Ligand Pharmaceuticals Incorporated (LGND): Price and Financial Metrics
LGND Price/Volume Stats
| Current price | $72.52 | 52-week high | $94.57 |
| Prev. close | $78.87 | 52-week low | $49.24 |
| Day low | $72.50 | Volume | 131,200 |
| Day high | $78.70 | Avg. volume | 159,073 |
| 50-day MA | $75.23 | Dividend yield | N/A |
| 200-day MA | $66.91 | Market Cap | 1.28B |
LGND Stock Price Chart Interactive Chart >
Ligand Pharmaceuticals Incorporated (LGND) Company Bio
Ligand Pharmaceuticals develops therapies that address the unmet medical needs of patients for a range of diseases, including hepatitis, multiple myeloma, muscle wasting, Alzheimers disease, dyslipidemia, diabetes, anemia, epilepsy, focal segmental glomerulosclerosis, and osteoporosis. The company was founded in 1987 and is based in La Jolla, California.
Latest LGND News From Around the Web
Below are the latest news stories about LIGAND PHARMACEUTICALS INC that investors may wish to consider to help them evaluate LGND as an investment opportunity.
13 Most Promising Small-Cap Stocks According to AnalystsIn this piece, we will take a look at the 13 most promising small-cap stocks according to analysts. If you want to skip our overview of small cap investing and the latest stock market news, then you can take a look at the 5 Most Promising Small-Cap Stocks To Buy. Within the broader world of […] |
Ligand Pharmaceuticals (LGND) Just Overtook the 200-Day Moving AverageGood things could be on the horizon when a stock surpasses the 200-day simple moving average. How should investors react? |
Ligand (LGND) Posts Long-Term Outlook, Updates Portfolio ProgressLigand (LGND) aims to generate annual core sales of around $290 million by 2028. It expects revenues from royalties to witness a CAGR of 16% over the next five years. |
Ligand Holds Investor and Analyst Day; Provides Update on Portfolio Progress and Recent Transactions; Introduces 2024 GuidanceSAN DIEGO, December 12, 2023--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) hosted an Investor and Analyst Day in New York City earlier today. CEO Todd Davis and other members of Ligand’s senior management team provided an overview of the company’s business model and investment selection process, reviewed the progress of the portfolio including near-term partner milestones, and introduced 2024 guidance. A copy of the presentation and a replay of the webcast are available at investor.ligand. |
Sermonix Pharmaceuticals Shares Pharmacokinetic and Baseline Genomic Clinical Data Tied to ELAINE Lasofoxifene Trials of Patients With ESR1 MutationsThree posters examining ELAINE clinical trials were presented last week at SABCSCOLUMBUS, Ohio, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers (mBC) harboring ESR1 mutations, today broadly shared the three poster presentations examining clinical data tied to Sermonix’s Evaluation of Lasofoxifene in ESR1 Mutations (ELAINE) studies. The presentations were |
LGND Price Returns
| 1-mo | -0.81% |
| 3-mo | 0.00% |
| 6-mo | 39.22% |
| 1-year | -5.54% |
| 3-year | -50.59% |
| 5-year | -40.61% |
| YTD | 1.54% |
| 2023 | 6.92% |
| 2022 | -56.75% |
| 2021 | 55.31% |
| 2020 | -4.64% |
| 2019 | -23.15% |
Continue Researching LGND
Want to do more research on Ligand Pharmaceuticals Inc's stock and its price? Try the links below:Ligand Pharmaceuticals Inc (LGND) Stock Price | Nasdaq
Ligand Pharmaceuticals Inc (LGND) Stock Quote, History and News - Yahoo Finance
Ligand Pharmaceuticals Inc (LGND) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...